This segment focuses on the research, development, and manufacturing of human and animal vaccines and drugs. Dyadic utilizes its proprietary C1 technology to produce various proteins, including virus-like particles, antigens, monoclonal antibodies, and therapeutic enzymes. The company is actively advancing its internal product pipeline, with a focus on developing next-generation multivariant COVID-19 vaccine candidates. Research and development activities include preclinical studies, clinical trials, and collaborations with various research institutions and pharmaceutical companies. The company aims to address unmet medical needs by providing effective and affordable solutions for global health. Future opportunities include expanding the product pipeline and securing regulatory approvals for its vaccine candidates and other therapeutic proteins. Partnerships with companies like Medytox, Inc. and Syngene International Limited are key to the development and commercialization of COVID-19 vaccines and boosters.

Dyadic's industrial applications segment focuses on the development and commercialization of enzymes and proteins for various industrial applications. This includes the production of enzymes for biofuel production, food processing, and other industrial processes. The company utilizes its C1 technology to create efficient and cost-effective protein production platforms. Research and development activities include optimizing protein production, improving enzyme stability, and developing new enzyme formulations. The company aims to provide sustainable and environmentally friendly solutions for industrial applications. Market positioning involves targeting industries that require high-performance enzymes and proteins. Future opportunities include expanding into new industrial sectors and developing novel enzyme products. The company has received patents for enzyme composition and development to convert plant biomass into fermentable sugars, demonstrating its commitment to innovation in this area.